Financials data is unavailable for this security.
View more
Year on year CG Oncology Inc had net income fall 37.14% from a loss of 35.44m to a larger loss of 48.61m despite a 6.81% increase in revenues from 191.00k to 204.00k. An increase in the selling, general and administrative costs as a percentage of sales from 3,354.97% to 4,853.43% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -9,870.92% |
| Operating margin | -12,572.92% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at CG Oncology Inc fell by 79.88m. Cash Flow from Financing totalled 87.00m or 42,645.59% of revenues. In addition the company used 45.68m for operations while cash used for investing totalled 121.20m.
| Cash flow per share | -1.17 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.29 |
|---|---|
| Tangible book value per share | 8.29 |
More ▼
Balance sheet in USDView more
| Current ratio | 47.57 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
